⌘K

Loading...

/News/RNS

Merger Update: AstraZeneca / Alexion

RNS Announcement

RNS Number : 0883F

Competition and Markets Authority

14 July 2021

Merger Clearance:

The CMA has decided, on the information currently available to it, not to refer the following merger to a Phase 2 investigation under the provisions of the Enterprise Act 2002:

Title of Merger case: Anticipated acquisition by AstraZeneca plc of Alexion Pharmaceuticals, Inc.

The text of this decision will be placed on the Competition and Markets Authority's web site at https://www.gov.uk/cma-cases as soon as is reasonably practicable.

In the event of media enquiries please email Press@cma.gov.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MERKZGMNGFRGMZM

RNS metadata

Title: Merger Update: AstraZeneca / Alexion
Time: 07:00:02
Date: 14 Jul 2021
Category: Acquisitions and alliances
ID: 0883F